Fundraising Fox
Salarius
3 known investors
Find your way into Salarius
Sign up to see every warm intro you have to Salarius
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Salarius team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
Investors · 3
Frequently asked questions
- What does Salarius do?
- Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
- Who are Salarius's investors?
- Salarius's investors include Central Texas Angel Network, Cowtown Angels, Dellin Investments.